This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Review  • Neurology, Other  • Alert me on articles by topic

Yukio Ando, MD; Masaaki Nakamura, MD; Shukuro Araki, MD

Arch Neurol. 2005;62:1057-1062.

Transthyretin-related familial amyloidotic polyneuropathy (FAP) is a fatal hereditary amyloidosis. Until 20 years ago, FAP was thought to be restricted to endemic occurrence in certain areas. However, owing to progress in biochemical and molecular genetic analyses, FAP is now believed to occur worldwide. As of today, reports of about 100 different points of single or double mutations, or a deletion in the transthyretin gene, have been published, and several different phenotypes of FAP have been documented, even for the same mutation in the transthyretin gene. We present herein the current clinicopathological, biochemical, molecular genetic, and epidemiological aspects of transthyretin-related FAP, and we introduce a new diagnostic procedure for the disease.

Author Affiliations: Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan (Drs Ando and Nakamura); and Department of Neurology, Ohmuta Tenryo Hospital, Ohmuta Fukuoka, Japan (Dr Araki).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Case of Polyneuropathy and Proteinuria
Korbet and Bonsib
CJASN 2008;3:624-636.
FULL TEXT